SCHEMBL6741747

SCHEMBL6741747

C[C@@H](O)c1cccc(Cl)c1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
NFKB1 P19838 2/20 0.44
PNMT P11086 1/20 0.44
LMNA P02545 2/20 0.42
ALDH1A1 P00352 1/20 0.42
GLA P06280 1/20 0.42
ADRB2 P07550 2/20 0.41
ADRB1 P08588 2/20 0.41
PDE2A O00408 1/20 0.38
AOC3 Q16853 1/20 0.37
HIF1A Q16665 2/20 0.37
BLM P54132 2/20 0.37
GABRA1 P14867 2/20 0.37
GABRG2 P18507 2/20 0.37
GABRB3 P28472 2/20 0.37
FAAH O00519 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20275286 1.00 CYP1A2 (0.44) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL21150479 0.84 GABRA1 (0.44) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL22791943 0.83 CYP1A2 (0.47) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL16961199 0.79 CYP1A2 (0.44) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL6744813 0.79 ADRB2 (0.41) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL7546175 0.78 CYP1A2 (0.63) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL10751510 0.78 GABRA1 (0.39) CYP1A2CYP3A4LMNAALDH1A1HIF1A
SCHEMBL316799 0.78 ADRB2 (0.55) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL342944 0.78 ADRB2 (0.55) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL29633572 0.78 ADRB2 (0.55) CYP1A2CYP3A4CYP2D6NFKB1PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2374794-B1 CYCLIC AMINE COMPOUNDS DAIICHI SANKYO CO LTD (JP) 2015-11-04 EP disclosed
EP-2374788-B1 INDANYL COMPOUNDS DAIICHI SANKYO CO LTD (JP) 2013-04-03 EP disclosed
US-8183272-B2 Indanyl compounds DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-05-22 US disclosed
US-8183272-B2 Indanyl compounds DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-05-22 US disclosed
US-8173631-B2 Cyclic amine compounds DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-05-08 US disclosed
US-8173631-B2 Cyclic amine compounds DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-05-08 US disclosed
US-20110319468-A1 CYCLIC AMINE COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-29 US disclosed
US-20110319468-A1 CYCLIC AMINE COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-29 US disclosed
US-20110319359-A1 INDANYL COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-29 US disclosed
US-20110319359-A1 INDANYL COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-29 US disclosed
EP-2374788-A1 INDANYL COMPOUNDS Daiichi Sankyo Company, Limited (JP) 2011-10-12 EP disclosed
EP-2374794-A1 CYCLIC AMINE COMPOUNDS Daiichi Sankyo Company, Limited (JP) 2011-10-12 EP disclosed
WO-2010074089-A1 INDANYL COMPOUNDS 第一三共株式会社 (JP) 2010-07-01 WO disclosed
WO-2010074088-A1 CYCLIC AMINE COMPOUNDS 第一三共株式会社 (JP) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319468-A1 CYCLIC AMINE COMPOUNDS RYR2, CASR, RYR1 CYP1A2 980/4885CYP3A4 792/4885CYP2D6 722/4885
US-20110319359-A1 INDANYL COMPOUNDS RYR2, ORAI1, CASR CYP1A2 649/4885CYP3A4 373/4885CYP2D6 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.